Clinical trial · Observational
Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With AML
Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients Followed for AML Treated With Oral Targeted Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): investigator's unavailability
Summary
Brief summary (as posted)
Advanced Practice Nurse (APN) is a new contributor in the French healthcare system. APN is part of a multidisciplinary team and aim to monitor patients under the coordination of the doctor particularly in onco-hematology. The aim of the study is to describe the different perceptions and expectations of APN monitoring according to patients with acute myeloid leukemia (AML) and their care team. This study will involve 10 patients, recruited over a provisional period of 5 months and 25 member of care team. Patients and their care team will be asked about their perceptions and expectations of APN participation in (AML monitoring) during a semi-structured interviews.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myeloid Leukemia | Myeloid Leukemia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Interviews | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Patients
- interventionNames
- Other: Interviews
- label
- medical staff
- interventionNames
- Other: Interviews
Primary outcomes (1)
- measure
- Perception of patient
- timeFrame
- Within 1 month
- description
- Semi-structured interview about perceptions and expectations of Advanced Practice Nurse (APN) participation in acute myeloid leukemia (AML) monitoring according to patient.
Secondary outcomes (1)
- measure
- Perception of care team
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with AML * Treated with a new targeted oral therapy as monotherapy or in combination: * Venetoclax\* in combination with ivosidenib (IDH1 inhibitor) * Onureg\* (azacitin: pyrimidine analogue) * Venetoclax (BCL-2 protein inhibitor) in combination with subcutaneous azacitin * Whose follow-up is provided alternately by a hematologist and an IPA. * Affiliated to a social security scheme Exclusion Criteria: * Moderate or severe cognitive impairment * Language barrier * Other communication disorders
References
Publications (0)
Data not yet available